Blueprint specializes in systemic mastocytosis, a rare immunological disease, and other Kit-driven diseases. With this ...

Circle Internet Group, Novo Nordisk A/S, Blueprint Medicines, Prologis, Blackstone, Apollo Global Management, and Welltower are the seven Growth stocks to watch today, according to MarketBeat’s stock ...

This week on "The Readout LOUD" podcast: an AI experiment at the FDA and how Novo Nordisk is trailing in the obesity drug ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Citizens JMP analyst Reni Benjamin downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Market Perform from Outperform ...

Stephens & Co. analyst Sudan Loganathan downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Equal Weight from ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

VersaBank (VBNK.T) is expected to report $0.27 for 2Q. Powered by Onclusive and Dow Jones. Advance Auto Parts Raised to Neutral From Sell by Redburn Atlantic ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Fintel reports that on June 3, 2025, JMP Securities downgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from ...